Imperial Line
Dry Eye Disease
Commercial/DevelopmentActive
Key Facts
About NTC
NTC is a private, R&D-focused Italian pharmaceutical company that has established itself as a leading European player in ophthalmic therapeutic solutions. Founded in 1990, the company has achieved significant growth, now distributing over 40 million units annually through a network of over 300 distributors in more than 100 countries. Its strategy is built on internal innovation, strategic acquisitions (like Pharmathen's ophthalmology business), and securing regulatory certifications (MDR for 20 devices) to strengthen its portfolio and market access.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| CyclASol® | Novaliq | Approved |
| NovaTears® | Novaliq | Commercial |